Curcumin Alleviates Myocardial Ischaemia–Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis via the Nrf2/HO‐1 Pathway: An Integrated Network Pharmacology and Experimental Study
Basic & Clinical Pharmacology & Toxicology · 2026-06 · 138 (6)
DOI: 10.1111/bcpt.70232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, online erschienen am 23.04.2026. Verfasst von Lingling Yao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Coronary Artery Disease (CCAD), Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical Unive…. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Myocardial Reperfusion Injury, Curcumin, Pyroptosis. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Scientific Research Project of the Department of Education of Hubei Province.
Abstract (Originalsprache)
Objective
This study aims to screen potential targets of Curcumin (Cur) in Myocardial ischaemia–reperfusion injury (MIRI) using network pharmacology and molecular docking, and to experimentally validate whether Cur mitigates MIRI by modulating the NLRP3 inflammasome and pyroptosis via the Nrf2/HO‐1 pathway.
Methods
Potential Cur–MIRI targets were identified from public databases and analysed by topological algorithms; molecular docking assessed binding affinity. Cardioprotective effects were validated in vivo using a murine LAD ligation model (30 min ischaemia/24 h reperfusion) and in vitro using H9C2 cardiomyocytes subjected to hypoxia/reoxygenation (H/R). Cur was given as pretreatment. Mechanistic assays included tissue immunofluorescence, mtROS and JC‐1 staining, ELISA for cytokines, and Western blotting; Nrf2 was silenced by siRNA to test dependency.
Results
Network analysis revealed 481 common targets enriched in apoptosis, TNF and NOD‐like receptor pathways. Docking showed favourable binding to NLRP3 (−8.14 kcal/mol) and Nrf2 (−7.02 kcal/mol). In vivo Cur reduced myocardial injury markers, improved echocardiographic function, attenuated inflammation and mitochondrial ultrastructural damage, and decreased NLRP3/caspase‐1 expression. In vitro Cur lowered IL‐1β/IL‐18 and mtROS, preserved mitochondrial membrane potential, reduced apoptosis, upregulated Nrf2/HO‐1 and downregulated pyroptosis proteins (NLRP3, ASC, caspase‐1, GSDMD). Nrf2 silencing abolished these effects.
Conclusion
Combining in silico and experimental evidence, Cur attenuates MIRI by activating Nrf2/HO‐1 to inhibit NLRP3 inflammasome‐mediated pyroptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Coronary Artery Disease (CCAD), Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- Department of Cardiology, Renmin Hospital, Hubei University of Medicine, Shiyan, China.
- Department of Hematology, Renmin Hospital, Hubei University of Medicine, Shiyan, China.
ORCID-Profile: Jinghua Liu
Förderung
- Scientific Research Project of the Department of Education of Hubei Province
Zitieren
APA
Yao, L., Qin, J., Shen, J., Zhang, F., & Liu, J. (2026). Curcumin Alleviates Myocardial Ischaemia–Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis via the Nrf2/HO‐1 Pathway: An Integrated Network Pharmacology and Experimental Study. Basic & Clinical Pharmacology & Toxicology, 138(6). https://doi.org/10.1111/bcpt.70232
Vancouver
Yao L, Qin J, Shen J, Zhang F, Liu J. Curcumin Alleviates Myocardial Ischaemia–Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis via the Nrf2/HO‐1 Pathway: An Integrated Network Pharmacology and Experimental Study. Basic & Clinical Pharmacology & Toxicology. 2026;138(6). doi:10.1111/bcpt.70232
BibTeX
@article{Yao2026,
author = {Yao, Lingling and Qin, Jun and Shen, Jun and Zhang, Fusheng and Liu, Jinghua},
title = {Curcumin Alleviates Myocardial Ischaemia–Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Pyroptosis via the Nrf2/HO‐1 Pathway: An Integrated Network Pharmacology and Experimental Study},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
volume = {138},
number = {6},
doi = {10.1111/bcpt.70232}
}
EUVIMED